scholarly journals Survival Benefit of Traditional Chinese Herbal Medicine (A Herbal Formula for Invigorating Spleen) in Gastric Cancer Patients with Peritoneal Metastasis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Lu Zhao ◽  
Ai-Guang Zhao ◽  
Gang Zhao ◽  
Yan Xu ◽  
Xiao-Hong Zhu ◽  
...  

Objective.We evaluated the efficiency of traditional Chinese herbal medicine (a compound herbal formula for invigorating spleen) as a complementary and alternative therapy for gastric cancer patients with peritoneal metastasis.Methods.Between 2001 and 2012, 93 gastric cancer patients with peritoneal metastasis were enrolled in this study. The effect of traditional Chinese herbal medicine on their long-term outcome was investigated. Kaplan-Meier method was used to assess the difference in survival time, and Cox proportional hazards regression analysis was performed to identify independent prognostic factors.Result.First-line palliative chemotherapy plus traditional Chinese herbal medicine was performed in 47 patients and the other 46 patients received chemotherapy alone. The overall survival was different between patients with and without traditional Chinese herbal medicine (12.0 versus 10.5 months;P=0.046). According to the Cox proportional hazard model, first-line chemotherapy cycle (hazards ratio [HR] = 0.527; 95% CI = 0.323~0.860) and TCHM (hazards ratio [HR] = 0.644; 95% CI = 0.481~0.992) were selected as independent prognostic factors for survival.Conclusion.The results suggest that traditional Chinese herbal medicine could improve the prognosis of the gastric cancer patients with peritoneal metastasis.

2020 ◽  
Author(s):  
Xin Li ◽  
Ling Chen ◽  
Xiaoqiang Gu ◽  
Jiahua Xu ◽  
Hongwei Li ◽  
...  

Abstract Background Traditional Chinese herbal medicine (TCHM) is widely used in the treatment of pancreatic cancer in China. In this retrospective study, the authors mainly analyzed the effect of TCHM on the survival time of patients with pancreatic cancer. Methods From 2011 to 2018, 121 pancreatic cancer patients were enrolled in this study. All patients were divided into either the TCHM group or non-TCHM group based on received TCHM or not. TCHM group received three months or more of TCHM treatment on the basis of comprehensive treatment. Kaplan-Meier method was used to assess the difference in survival time, and Cox proportional hazards regression analysis was performed to identify independent prognostic factors. Results The overall survival was different between all patients with and without TCHM (P = 0.000), COX analysis showed the clinical staging (P = 0.050), surgery (P = 0.000), chemotherapy (P = 0.000) and TCHM (P = 0.000) were independent prognostic factors. In a stratification analysis of stage for patients who received chemotherapy, there was a significant increase in median overall survival from 10.7 (non-TCHM group) to 19.5 (TCHM group) months (hazard ratio [HR] = 3.197, 95% confidence interval [CI] 1.989–5.137, P = 0.000). Patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 4.3 (non-TCHM group) to 15.1 (TCHM group) months (HR = 0.041, 95% CI = 0.005–0.329, P = 0.003). Conclusions TCHM was an important independent prognostic factor of pancreatic cancer and have an effect on improving the prognosis of pancreatic cancer patients.


2006 ◽  
Vol 34 (05) ◽  
pp. 833-844 ◽  
Author(s):  
Lixing Lao ◽  
Arthur Yin Fan ◽  
Rui-Xin Zhang ◽  
Annan Zhou ◽  
Zhong-Ze Ma ◽  
...  

Chinese herbal medicine has been used for thousands of years in China and other Asian countries to treat a variety of inflammatory diseases. The classic Chinese herbal formula, Huo Luo Xiao Ling Dan (活络效灵丹, HLXL) is commonly used in traditional Chinese herbal medicine for the treatment of joint pain and other symptoms of arthritis. The present study is an investigation of the effects of a modified HLXL extract on persistent hyperalgesia and edema in rats with peripheral inflammation. Inflammation was induced by injecting complete Freund's adjuvant (CFA) into one hind paw. Four dosages of the extract were compared to a vehicle control. Each was administered intragastrally (i.g.) daily for seven days beginning one day before CFA. Hyperalgesia was assessed using a paw withdrawal latency (PWL) test and edema was determined by measuring paw thickness at pre-CFA and 2 hours, 24 hours, and 5 days post-CFA. Immunohistochemistry was performed 2 hours post-CFA to determine spinal Fos protein expression. Adverse effects of the extract were monitored by observing the animals closely for unusual behavioral changes. Compared to the control, HLXL at the two lower dosages (0.575 g/kg and 1.15 g/kg) were effective in the later stage (day 5) of inflammatory hyperalgesia and edema, while the two higher dosages (2.3 g/kg and 4.6 g/kg) alleviated early stage hind paw inflammation and hyperalgesia and facilitated recovery from paw edema and hyperalgesia during the late stage. HLXL at 2.30 g/kg significantly suppressed Fos expression in laminae I–II, III–IV and V–VI ipsilaterally and in III-IV contralaterally. No significant signs of toxicity or adverse effects were observed. The data suggest that HLXL dosage-dependently attenuates CFA-induced inflammation and hyperalgesia, at least in part by inhibiting noxious transmission at the dorsal horn of the spinal cord.


2013 ◽  
Vol 406 (5) ◽  
pp. 1481-1491 ◽  
Author(s):  
Lina Chen ◽  
Fengrui Song ◽  
Zhiqiang Liu ◽  
Zhong Zheng ◽  
Junpeng Xing ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document